What is the difference between BPC-157 and TB-500?

BPC-157: BPC-157 is believed to accelerate angiogenesis and upregulate growth hormone receptors locally at injury sites. TB-500: TB-500 exerts its effects primarily through promotion of actin polymerisation and cell migration.

Is BPC-157 FDA approved?

BPC-157 is not FDA approved and restricted from compounding. It is discussed for research and educational purposes only, not as medical guidance.

Is TB-500 FDA approved?

TB-500 is not FDA approved and restricted from compounding. It is discussed for research and educational purposes only, not as medical guidance.

How is BPC-157 administered in research settings?

In research settings, BPC-157 is typically administered via the subcutaneous or oral routes. PeptideBase does not provide dosing or administration instructions.

How is TB-500 administered in research settings?

In research settings, TB-500 is typically administered via the subcutaneous route. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›BPC-157 vs TB-500

Peptide Comparison

BPC-157 vs TB-500

Name: BPC-157 vs TB-500 — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

Both are Tissue Repair peptides.

BPC-157

Body Protection Compound 157

RecoveryBanned from CompoundingResearch Only

Half-life: Under 30 minutes (plasma); no human PK data

635 providers listed

Full BPC-157 profile →

TB-500

thymosin beta 4

RecoveryBanned from CompoundingResearch Only

Half-life: 5–7 days

402 providers listed

Full TB-500 profile →

Bottom line

BPC-157 carries stronger published evidence (Cohort study, 10 key studies) than TB-500 (Review, 3); both are research compounds.

Quick Verdict

BPC-157

Evidence

Emerging Clinical

Half-life

Under 30 minutes (plasma); no human PK data

TB-500

Evidence

Preclinical

Half-life

5–7 days

Which One Should You Choose?

Your goal	Better option
GI tract and gut lining repair research	BPC-157
Systemic and cardiovascular tissue repair research	TB-500
Neurological protection research (animal models)	BPC-157
Broad actin-regulatory mechanism (systemic reach)	TB-500
More provider options (635 vs 402)	BPC-157
Anti-inflammatory effect in animal model research	BPC-157

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

BPC-157

TB-500

Mechanism Family

Tissue Repair

Half-life

Under 30 minutes (plasma); no human PK data

5–7 days

FDA Status

banned from compounding

Admin Routes

subcutaneous, oral

subcutaneous

Availability

Research Only

Providers

635 listed

402 listed

FDA Update

Sep 2023

Dec 2023

Avail. Notes

Not FDA-approved for any human use; sold as a research chemical; WADA prohibited (S0). Placed on the interim FDA 503A "Category 2" list (significant safety risks) in September 2023. In February 2026 HHS announced an intention to move several peptides toward "Category 1," but the FDA did not reclassify BPC-157. In April 2026 the FDA removed BPC-157 from the Category 2 list because the nomination was withdrawn — this does not authorize compounding, and BPC-157 is not on the 503A bulks list. The FDA's Pharmacy Compounding Advisory Committee is scheduled to review BPC-157 on July 23–24, 2026. Provider pricing varies by concentration, formulation, and source; use the PeptideBase directory to compare active providers and current availability.

Not FDA-approved; WADA prohibited (S2). Placed on the interim FDA 503A "Category 2" list (significant safety risks) in September 2023, alongside BPC-157. The FDA did not reclassify it to "Category 1" in February 2026 (that was an HHS announcement of intent, not an FDA action). In April 2026 the FDA removed the thymosin β4 fragment (TB-500) from Category 2 because the nomination was withdrawn — this does not authorize compounding. The FDA's Pharmacy Compounding Advisory Committee is scheduled to review TB-500 on July 23–24, 2026.

Research Evidence

BPC-157

Emerging ClinicalCohort study · 10 key studies · most recent 2026

TB-500

PreclinicalReview · 3 key studies · most recent 2019

Research Citations

BPC-157

Cohort2026 · J Clin Med

Endothelium-Dependent Nitric Oxide-Mediated Vasorelaxant Effects of BPC 157 in Human Internal Mammary Artery.

Cohort2026 · Sci Rep

Protective effects of BPC 157 in rats with experimentally induced lower extremity ischemia-reperfusion injury.

Review2026 · Pharmaceutics

BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and…

Cohort2026 · Pharmaceuticals (Basel)

Unilateral Adrenalectomy, and the Stable Pentadecapeptide BPC 157 as Therapy in Rats-A Cytoprotection Approac…

+6 more

TB-500

Review2019 · Canadian Journal of Physiology and Pharmacology

Tβ4-Ac-SDKP pathway: Any relevance for the cardiovascular system?

Animal2013 · Kidney International

Thymosin β4 and its degradation product, Ac-SDKP, are novel reparative factors in renal fibrosis

Animal2003 · Wound Repair and Regeneration

Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db…

About BPC-157

BPC-157 is believed to accelerate angiogenesis and upregulate growth hormone receptors locally at injury sites. It appears to promote fibroblast migration and collagen synthesis, contributing to faster tissue remodelling. Animal studies suggest systemic effects via modulation of the dopaminergic and serotonergic systems, though human data remain limited.

Research Areas

tissue repair across tendon, muscle, nerve, and gut — most broadly studied recovery peptideanti-inflammatory via COX-2 and NF-κB pathway modulationangiogenesis and wound healing via VEGF and nitric oxide system upregulationoral or subcutaneous administration studied — systemic and local tissue effects documented

About TB-500

TB-500 exerts its effects primarily through promotion of actin polymerisation and cell migration. It upregulates the expression of beta-4 thymosin, which facilitates endothelial and muscle satellite cell movement to injury sites. Unlike BPC-157, TB-500 appears to act via a more systemic mechanism rather than locally at the administration site.

Research Areas

actin binding and cellular migration facilitation — core mechanism driving tissue repairwound healing and anti-inflammatory effects across muscle, tendon, and cardiac tissuethymosin beta-4 C-terminal fragment — angiogenesis and systemic distributionsubcutaneous injection — frequently combined with BPC-157 in recovery research stacks

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

BPC-157

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

Regulatory Notes

global — WADA

BPC-157 is on the WADA Prohibited List at all times (S0, Non-Approved Substances), effective 1 January 2022. It has no FDA approval and no adequate human clinical trial.

source

TB-500

Absolute Contraindications

Under clinical review

Being verified by our medical team before we display contraindications for this peptide.

Regulatory Notes

global — WADA

TB-500 / thymosin β4 is on the WADA Prohibited List at all times (S2.3, Growth Factors), effective 2018. It has no FDA approval and no human RCT evidence for injectable use.

source

Used Together?

Commonly stacked

Well Documented

BPC-157 and TB-500 are reported to work together. Research suggests BPC-157 and TB-500 may produce enhanced tissue repair effects when combined. BPC-157 is studied for angiogenesis and gut-protective properties, while TB-500 promotes actin assembly and cell migration — complementary mechanisms in healing models.

BPC-157

GHK-Cu
Research suggests GHK-Cu and BPC-157 may produce complementary tissue repair and anti-inflammatory effects when combined. GHK-Cu is studied for copper-dependent collagen synthesis and antioxidant gene activation, while BPC-157 supports angiogenesis and growth factor expression.
TB-500
Research suggests BPC-157 and TB-500 may produce enhanced tissue repair effects when combined. BPC-157 is studied for angiogenesis and gut-protective properties, while TB-500 promotes actin assembly and cell migration — complementary mechanisms in healing models.
Anticoagulants / blood thinners
Research notes that BPC-157 promotes angiogenesis and may influence platelet and vascular function in healing models. Combined use with anticoagulant medications may warrant monitoring. Consult your prescriber before combining.

TB-500

BPC-157
Research suggests BPC-157 and TB-500 may produce enhanced tissue repair effects when combined. BPC-157 is studied for angiogenesis and gut-protective properties, while TB-500 promotes actin assembly and cell migration — complementary mechanisms in healing models.

Price (per mg)

BPC-157

$6.23/mg

$4.12 – $9.00 range

88 vendors

View price index →Find providers →

TB-500

$7.00/mg

$5.00 – $10.00 range

86 vendors

View price index →Find providers →

Find Providers

Where to source these peptides

Providers offering

BPC-157

635 listed

Browse directory →

Providers offering

TB-500

402 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Tissue Repair Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated July 20, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). BPC-157 vs TB-500 — Per-mg Price Comparison. Retrieved July 22, 2026, from https://peptidebase.io/peptides/compare/bpc-157/tb-500

https://peptidebase.io/peptides/compare/bpc-157/tb-500 Methodology License Download JSON Download CSV